Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 7043429, 12 pages
https://doi.org/10.1155/2017/7043429
Research Article

A Reduction in Selenoprotein S Amplifies the Inflammatory Profile of Fast-Twitch Skeletal Muscle in the mdx Dystrophic Mouse

1Institute for Physical Activity and Nutrition Research (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Geelong, VIC, Australia
2Molecular Medical Research SRC, School of Medicine, Deakin University, Geelong, VIC, Australia
3Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia

Correspondence should be addressed to Craig Robert Wright; ua.ude.nikaed@thgirw.giarc

Received 29 November 2016; Revised 23 February 2017; Accepted 7 March 2017; Published 16 May 2017

Academic Editor: Mirella Giovarelli

Copyright © 2017 Craig Robert Wright et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. G. Tidball and S. A. Villalta, “Regulatory interactions between muscle and the immune system during muscle regeneration,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol. 298, no. 5, pp. R1173–R1187, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. A. L. Serrano, B. Baeza-Raja, E. Perdiguero, M. Jardí, and P. Muñoz-Cánoves, “Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy,” Cell Metabolism, vol. 7, no. 1, pp. 33–44, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. S. E. Chen, B. Jin, and Y. P. Li, “TNF-α regulates myogenesis and muscle regeneration by activating p38 MAPK,” American Journal of Physiology-Cell Physiology, vol. 292, no. 5, pp. C1660–C1671, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Costamagna, P. Costelli, M. Sampaolesi, and F. Penna, “Role of inflammation in muscle homeostasis and myogenesis,” Mediators of Inflammation, vol. 2015, Article ID 805172, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Mojumdar, F. Liang, C. Giordano et al., “Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CCR2,” EMBO Molecular Medicine, vol. 6, no. 11, pp. 1476–1492, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. G. D. Thomas, “Functional muscle ischemia in Duchenne and Becker muscular dystrophy,” Frontiers in Physiology, vol. 4, no. 381, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. W. Chen, K. Nagaraju, M. Bakay et al., “Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy,” Neurology, vol. 65, no. 6, pp. 826–834, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Ishitobi, K. Haginoya, Y. Zhao et al., “Elevated plasma levels of transforming growth factor β1 in patients with muscular dystrophy,” Neuroreport, vol. 11, no. 18, pp. 4033–4035, 2000. View at Google Scholar
  9. M. Yamazaki, S. Minota, H. Sakurai et al., “Expression of transforming growth factor-beta 1 and its relation to endomysial fibrosis in progressive muscular dystrophy,” The American Journal of Pathology, vol. 144, no. 2, pp. 221–226, 1994. View at Google Scholar
  10. S. Kuru, A. Inukai, T. Kato, Y. Liang, S. Kimura, and G. Sobue, “Expression of tumour necrosis factor-α in regenerating muscle fibers in inflammatory and non-inflammatory myopathies,” Acta Neuropathologica, vol. 105, no. 217, p. 224, 2003. View at Publisher · View at Google Scholar
  11. B. De Paepe, K. K. Creus, J. J. Martin, and J. L. De Bleecker, “Upregulation of chemokines and their receptors in Duchenne muscular dystrophy: potential for attenuation of myofiber necrosis,” Muscle & Nerve, vol. 46, no. 6, pp. 914–916, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Rufo, A. Del Fattore, M. Capulli et al., “Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans,” Journal of Bone and Mineral Research, vol. 26, no. 8, pp. 1891–1903, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. J. V. Hartel, J. A. Granchelli, M. S. Hudecki, C. M. Pollina, and L. E. Gosselin, “Impact of prednisone on TGF-á1 and collagen in diaphragm muscle from mdx mice,” Muscle & Nerve, vol. 24, no. 3, pp. 428–432, 2001. View at Publisher · View at Google Scholar
  14. M. D. Grounds and J. Torrisi, “Anti-TNFα (Remicade) therapy protects dystrophic skeletal muscle from necrosis,” The FASEB Journal, vol. 18, no. 6, pp. 676–682, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Hnia, J. Gayraud, G. Hugon et al., “L-arginine decreases inflammation and modulates the nuclear factor-κB/matrix metalloproteinase cascade in mdx muscle fibers,” The American Journal of Pathology, vol. 172, no. 6, pp. 1509–1519, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Dadgar, Z. Wang, H. Johnston et al., “Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy,” The Journal of Cell Biology, vol. 207, no. 1, pp. 139–158, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Vandevyver, L. Dejager, J. Tuckermann, and C. Libert, “New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation,” Endocrinology, vol. 154, no. 3, pp. 993–1007, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. I. Arpan, R. J. Willcocks, S. C. Forbes et al., “Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS,” Neurology, vol. 83, no. 11, pp. 974–980, 2014. View at Publisher · View at Google Scholar
  19. A. Y. Manzur, T. Kuntzer, M. Pike, and A. V. Swan, “Glucocorticoid corticosteroids for duchenne muscular dystrophy,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD003725, 2008. View at Google Scholar
  20. O. Schakman, S. Kalista, C. Barbe, A. Loumaye, and J. P. Thissen, “Glucocorticoid-induced skeletal muscle atrophy,” The International Journal of Biochemistry & Cell Biology, vol. 45, no. 10, pp. 2163–2172, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. K. R. Short, M. L. Bigelow, and K. S. Nair, “Short-term prednisone use antagonizes insulin’s anabolic effect on muscle protein and glucose metabolism in young healthy people,” American Journal of Physiology-Endocrinology and Metabolism, vol. 297, no. 6, pp. E1260–E1268, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Yan, G. M. Anderson, M. DeWitte, and M. T. Nakada, “Therapeutic potential of cytokine and chemokine antagonists in cancer therapy,” European Journal of Cancer, vol. 42, no. 6, pp. 793–802, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. F. J. Pashkow, D. G. Watumull, and C. L. Campbell, “Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease,” The American Journal of Cardiology, vol. 101, no. 10, pp. S58–S68, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. C. R. Heier, J. M. Damsker, Q. Yu et al., “VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects,” EMBO Molecular Medicine, vol. 5, no. 10, pp. 1569–1585, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Tang, D. P. Reay, M. N. Salay et al., “Inhibition of the IKK/NF-κB pathway by AAV gene transfer improves muscle regeneration in older mdx mice,” Gene Therapy, vol. 17, no. 12, pp. 1476–1483, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Wehling, M. J. Spencer, and J. G. Tidball, “A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice,” The Journal of Cell Biology, vol. 155, no. 1, pp. 123–132, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. V. Malik, L. R. Rodino-Klapac, and J. R. Mendell, “Emerging drugs for Duchenne muscular dystrophy,” Expert Opinion on Emerging Drugs, vol. 17, no. 2, pp. 261–277, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Bonifati, S. F. Witchel, M. Ermani, E. P. Hoffman, C. Angelini, and E. Pegoraro, “The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 77, no. 10, pp. 1177–1179, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Pegoraro, E. P. Hoffman, L. Piva et al., “SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy,” Neurology, vol. 76, no. 3, pp. 219–226, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Piva, B. F. Gavassini, L. Bello et al., “TGFBR2 but not SPP1 genotype modulates osteopontin expression in Duchenne muscular dystrophy muscle,” The Journal of Pathology, vol. 228, no. 2, pp. 251–259, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Kee-Hong, Y. Gao, K. Walder, G. R. Collier, J. Skelton, and A. H. Kissebah, “SEPS1 protects RAW264.7 cells from pharmacological ER stress agent induced apoptosis,” Biochemical and Biophysical Research Communications, vol. 354, no. 127, 2007. View at Publisher · View at Google Scholar
  32. Y. Ye, Y. Shibata, C. Yun, D. Ron, and T. A. Rapoport, “A membrane protein complex mediates retro-translocation from the ER lumen into the cytosol,” Nature, vol. 429, no. 6994, pp. 841–847, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. J. E. Curran, J. B. Jowett, K. S. Elliott et al., “Genetic variation in selenoprotein S influences inflammatory response,” Nature Genetics, vol. 37, no. 11, pp. 1234–1241, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Du, H. Liu, and K. Huang, “Influence of SelS gene silence on β-mercaptoethanol-mediated endoplasmic reticulum stress and cell apoptosis in HepG2 cells,” Biochimica et Biophysica Acta-General Subjects, vol. 1800, no. 5, pp. 511–517, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Fradejas, M. Del Carmen Serrano‐Pérez, P. Tranque, and S. Calvo, “Selenoprotein S expression in reactive astrocytes following brain injury,” Glia, vol. 59, no. 6, pp. 959–972, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Y. Kim and K. H. Kim, “Dexamethasone-induced selenoprotein S degradation is required for adipogenesis,” Journal of Lipid Research, vol. 54, no. 8, pp. 2069–2082, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Gao, N. R. Hannan, S. Wanyonyi et al., “Activation of selenoprotein SEPS1 gene expression by pro-inflammatory cytokines in HepG2 cells,” Cytokine, vol. 33, no. 5, pp. 246–251, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. L. He, B. Wang, Y. Yao, M. Su, H. Ma, and N. Jia, “Protective effects of the SEPS1 gene on lipopolysaccharide-induced sepsis,” Molecular Medicine Reports, vol. 9, no. 5, pp. 1869–1876, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. V. Allamand, P. Richard, A. Lescure et al., “A single homozygous point mutation in a 3′ untranslated region motif of selenoprotein N mRNA causes SEPN1-related myopathy,” EMBO Reports, vol. 7, no. 4, pp. 450–454, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Walder, L. Kantham, M. M. JS et al., “Tanis: a link between type 2 diabetes and inflammation?” Diabetes, vol. 51, no. 6, pp. 1859–1866, 2002. View at Publisher · View at Google Scholar
  41. N. Stupka, J. D. Schertzer, R. Bassel-Duby, E. N. Olson, and G. S. Lynch, “Stimulation of calcineurin Aα activity attenuates muscle pathophysiology in mdx dystrophic mice,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol. 294, no. 3, pp. R983–R992, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Sejerson and K. Bushby, “Standards of care for Duchenne muscular dystrophy: brief TREAT-NMD recommendations,” Inherited Neuromuscular Diseases, Springer, Netherlands, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. S. S. Segal and J. A. Faulkner, “Temperature-dependent physiological stability of rat skeletal muscle in vitro,” American Journal of Physiology-Cell Physiology, vol. 248, no. 3, pp. C265–C270, 1985. View at Google Scholar
  44. S. V. Brooks and J. A. Faulkner, “Contractile properties of skeletal muscles from young, adult and aged mice,” The Journal of Physiology, vol. 404, p. 71, 1988. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Nsiah-Sefaa, E. L. Brown, A. P. Russell, and V. C. Foletta, “New gene targets of PGC-1α and ERRα co-regulation in C2C12 myotubes,” The Journal of Physiology, vol. 404, no. 1, p. 71, 1988. View at Publisher · View at Google Scholar · View at Scopus
  46. G. M. Camerino, M. Cannone, A. Giustino et al., “Gene expression in mdx mouse muscle in relation to age and exercise: aberrant mechanical–metabolic coupling and implications for pre-clinical studies in Duchenne muscular dystrophy,” Human Molecular Genetics, vol. 23, no. 21, pp. 5720–5732, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Briguet, I. Courdier-Fruh, M. Foster, T. Meier, and J. P. Magyar, “Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse,” Neuromuscular Disorders, vol. 14, no. 10, pp. 675–682, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. H. G. Radley-Crabb, J. C. Marini, H. A. Sosa, L. I. Castillo, M. D. Grounds, and M. L. Fiorotto, “Dystropathology increases energy expenditure and protein turnover in the mdx mouse model of Duchenne muscular dystrophy,” PloS One, vol. 9, Article ID 2, article e89277, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. F. O. Martinez and S. Gordon, “The M1 and M2 paradigm of macrophage activation: time for reassessment,” F1000Prime rep, vol. 6, no. 13.10, p. 12703, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Tierney, C. Garcia, M. Bancone, A. Sacco, and K. E. Personius, “Innervation of dystrophic muscle following muscle stem cell therapy,” Muscle & Nerve, vol. 54, no. 4, pp. 763–768, 2016. View at Publisher · View at Google Scholar · View at Scopus
  51. E. Folker and M. Baylies, “Nuclear positioning in muscle development and disease,” Frontiers in Physiology, vol. 4, p. 363, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Nilwik, T. Snijders, M. Leenders et al., “The decline in skeletal muscle mass with aging is mainly attributed to a reduction in type II muscle fiber size,” Frontiers in Physiology, vol. 4, no. 363, pp. 492–498, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Ciciliot, A. C. Rossi, K. A. Dyar, B. Blaauw, and S. Schiaffino, “Muscle type and fiber type specificity in muscle wasting,” The International Journal of Biochemistry & Cell Biology, vol. 45, no. 10, pp. 2191–2199, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. K. H. Kim, Y. Gao, K. Walder, G. R. Collier, J. Skelton, and A. H. Kissebah, “SEPS1 protects RAW264. 7 cells from pharmacological ER stress agent-induced apoptosis,” Biochemical and Biophysical Research Communications, vol. 354, no. 1, pp. 127–132, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Zeng, S. Du, J. Zhou, and K. Huang, “Role of SelS in lipopolysaccharide-induced inflammatory response in hepatoma HepG2 cells,” Archives of Biochemistry and Biophysics, vol. 478, no. 1, pp. 1–6, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. W. R. Frontera and J. Ochala, “Skeletal muscle: a brief review of structure and function,” Calcified Tissue International, vol. 96, no. 3, pp. 183–195, 2015. View at Publisher · View at Google Scholar · View at Scopus
  57. B. J. Petrof, “The molecular basis of activity-induced muscle injury in Duchenne muscular dystrophy,” Molecular and Cellular Biochemistry, vol. 179, no. 1-2, pp. 111–124, 1998. View at Google Scholar
  58. J. W. Carnwath and D. M. Shotton, “Muscular dystrophy in the mdx mouse: histopathology of the soleus and extensor digitorum longus muscles,” Journal of the Neurological Sciences, vol. 80, no. 1, pp. 39–54, 1987. View at Publisher · View at Google Scholar · View at Scopus
  59. J. D. Porter, S. Khanna, H. J. Kaminski et al., “A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice,” Human Molecular Genetics, vol. 11, no. 3, pp. 263–272, 2002. View at Publisher · View at Google Scholar
  60. V. Ljubicic and B. J. Jasmin, “AMP-activated protein kinase at the nexus of therapeutic skeletal muscle plasticity in Duchenne muscular dystrophy,” Trends in Molecular Medicine, vol. 19, no. 10, pp. 614–624, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. M. D. Grounds, H. G. Radley, G. S. Lynch, K. Nagaraju, and A. De Luca, “Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy,” Neurobiology of Disease, vol. 31, no. 1, pp. 1–19, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. G. L. Warren, T. Hulderman, D. Mishra et al., “Chemokine receptor CCR2 involvement in skeletal muscle regeneration,” The FASEB Journal, vol. 19, no. 3, pp. 413–415, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. D. J. Kominsky, E. L. Campbell, and S. P. Colgan, “Metabolic shifts in immunity and inflammation,” The Journal of Immunology, vol. 184, no. 8, pp. 4062–4068, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. U. Sharma, S. Atri, M. C. Sharma, C. Sarkar, and N. R. Jagannathan, “Skeletal muscle metabolism in Duchenne muscular dystrophy (DMD): an in-vitro proton NMR spectroscopy study,” Magnetic Resonance Imaging, vol. 21, no. 2, pp. 145–153, 2003. View at Publisher · View at Google Scholar · View at Scopus
  65. C. T. Taylor and S. P. Colgan, “Hypoxia and gastrointestinal disease,” Journal of Molecular Medicine, vol. 85, no. 12, pp. 1295–1300, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. W. Duddy, S. Duguez, H. Johnston et al., “Muscular dystrophy in the mdx mouse is a severe myopathy compounded by hypotrophy, hypertrophy and hyperplasia,” Skeletal Muscle, vol. 5, no. 1, p. 1, 2015. View at Publisher · View at Google Scholar · View at Scopus